Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Sunrun heads into its November earnings with a stock down 14% over the past month, a short position covering nearly a third of the float, and Goldman Sachs trimming its target for the third time since August.
The most telling event of the week was Goldman's decision to cut its price target again, from $13 to $11, while holding its Buy rating. Brian Lee made the same move on September 21, cutting from $15 to $13. Before that, Goldman took the target from $18 to $15 after the August earnings print. The direction of travel is clear: the firm is still constructive but losing conviction in the pace of recovery. The broader Street has moved the same way. Wells Fargo, Citi, TD Cowen and RBC all trimmed targets following the August results, though none pulled their positive ratings. GLJ Research sits alone on the other side with a Sell and a $4.63 target. The consensus mean sits at $15.86, more than double the current price of $7.61. That gap is as much a reflection of how far the stock has fallen as it is of analyst optimism.
Short interest is the dominant feature of the positioning picture, and it has been drifting higher. At 30.3% of the free float, it has climbed roughly 7.5% over the past month and ticked up again this week. The ORTEX short score of 68.9 sits well above neutral and has been running in the high 60s to low 70s for the past two weeks, consistent with sustained bearish conviction rather than a short-term tactical trade. Yet the borrow market tells a more nuanced story. Availability is loose at 311%, meaning there are roughly three shares available to lend for every two already borrowed, close to the highest level of the past year. Cost to borrow has crept up about 19% on the week to around 0.50%, but that remains a very cheap rate in absolute terms. Bears are not being squeezed out. The infrastructure to add more short exposure is comfortably in place.
Options positioning is mildly call-skewed, which sits in contrast to the heavily net short stock position. The put/call ratio at 0.40 is slightly above its 20-day average of 0.37 but only half a standard deviation above the mean. At the 52-week low end of the range, call volume has dominated the options market for most of the past year. That divergence between a bullish options tilt and a very large short position is the tension worth watching.
On the ownership side, executive selling clustered on October 6. CEO Mary Powell sold roughly 24,000 shares at $7.76, the CFO sold a similar number through a grant-and-sell sequence, and the Chief Legal Officer and President also sold. None of these appear to have been under 10b5-1 plans. The aggregate net insider position over 90 days is about negative 122,000 shares worth just over $1 million, not a dramatic sum, but the timing and breadth of the October 6 cluster is notable. Retail attention has picked up relative to Sunrun's own recent history, with a Wikipedia views z-score of 1.5 through late September, more eye-balls but not necessarily fresh buyers.
Valuation offers limited comfort. The price-to-book sits at 0.40 and has fallen about 16% over the past month. The EV/EBITDA multiple at 21x reflects the debt-heavy structure of a company with nearly $19 billion in enterprise value against a stock market cap that has collapsed. The EPS surprise factor score at the 90th percentile shows Sunrun has historically beaten estimates frequently, yet the 12-month forward earnings growth score ranks at the 3rd percentile, a signal that the Street sees little near-term earnings momentum regardless of the beat history.
The last earnings print on August 5 sent the stock down nearly 15% the next day and a further 11% over the following five trading sessions. The print before that, in May, produced a 10% bounce. With the next report due November 4, 27 days away, the setup to watch is whether the cash generation question that drove the August selloff can be addressed: the company guided $200 to $500 million in full-year cash generation for 2025 after delivering only $27 million in Q2 against guidance of $50 to $60 million, and how management frames Q3 progress on that metric will likely determine whether the stock can break out of its current range or retest the lows.
See the live data behind this article on ORTEX.
Open RUN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
